Avoid common mistakes on your manuscript.
Correction to: Adv Ther (2020) 37:4033–4042 https://doi.org/10.1007/s12325-020-01449-0
In the original article, there is an error in Fig. 1. The correct Fig. 1 is given below:
SVR12 rates in TN patients with CC, GT1–6a treated with 8 weeks of G/P. aScottish HCV study included GT1,2,4–6, US VA study included GT1–3. bFour patients were lost to follow-up in the ITT population. cOne confirmed reinfection with subsequent spontaneous clearance, no virologic failure. dOne virologic failure. eOne patient died after completing treatment but before SVR12 testing, one patient was lost to follow-up. fPatients missing SVR12 data were excluded from SVR12 analysis. CC compensated cirrhosis, DHC-R German Hepatitis C-Registry, G/P glecaprevir/pibrentasvir, GT genotype, HCV hepatitis C virus, ITT intention-to-treat, PMOS post-marketing observational studies, SVR12 sustained virologic response at week 12, TN treatment-naïve, VA Veterans Association
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Lampertico, P., Mauss, S., Persico, M. et al. Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. Adv Ther 37, 4755–4756 (2020). https://doi.org/10.1007/s12325-020-01482-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-020-01482-z